Unknown

Dataset Information

0

Visceral Adiposity in Psoriasis is Associated With Vascular Inflammation by 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Beyond Cardiometabolic Disease Risk Factors in an Observational Cohort Study.


ABSTRACT: OBJECTIVES:The authors sought to examine the relationship between visceral adipose tissue (VAT) and vascular inflammation (VI) by 18F-Fluorodeoxyglucose (18F-FDG) positron-emission tomography (PET)/computed tomography (CT) in psoriasis (PSO). Furthermore, we evaluated whether treatment of PSO modulated VAT and VI. BACKGROUND:PSO, a chronic inflammatory skin disease, is associated with VI by 18F-FDG PET/CT and increased cardiometabolic risk including adipose tissue dysregulation. Recently, VI was associated with future cardiovascular events; however, the relationship of visceral and subcutaneous adiposity with VI in PSO has yet to be evaluated. METHODS:Consecutive PSO patients (N = 77) underwent 18F-FDG PET/CT scans to measure VI and abdominal adiposity. A subset of PSO patients with severe skin disease was scanned at 1 year following PSO treatment (N = 13). RESULTS:The cohort was middle aged (51.8 ± 12.6 years), predominantly male (n = 44, 57%), had low cardiovascular risk by Framingham 10-year risk (median 4 years [interquartile range (IQR): 2 to 7 years]), and mild-to-moderate skin disease (5.2 [IQR: 3.0 to 8.5]). PSO disease severity associated with VAT (β = 0.33; p = 0.004) beyond SAT (β = 0.30; p = 0.005). VAT (β = 0.55; p < 0.001), but not SAT (β = 0.15; p = 0.11), associated with VI beyond cardiovascular risk factors. We followed a subset of severe PSO patients treated aggressively for PSO and observed improvement in PSO severity and VAT, which was associated with an improvement in VI at 1 year beyond cardiovascular risk factors (β = 0.53; p = 0.049). CONCLUSIONS:Volume-based CT measurement of VAT may capture metabolic risk associated with VI compared to subcutaneous adipose tissue in PSO. PSO treatment associated with a decrease in VAT as well as decrease in VI suggesting VAT as a relevant biomarker related to VI in PSO.

SUBMITTER: Rivers JP 

PROVIDER: S-EPMC5803350 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Visceral Adiposity in Psoriasis is Associated With Vascular Inflammation by <sup>18</sup>F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Beyond Cardiometabolic Disease Risk Factors in an Observational Cohort Study.

Rivers Joshua P JP   Powell-Wiley Tiffany M TM   Dey Amit K AK   Rodante Justin A JA   Chung Jonathan H JH   Joshi Aditya A AA   Natarajan Balaji B   Sajja Aparna P AP   Chaturvedi Abhishek A   Rana Anshuma A   Harrington Charlotte L CL   Teague Heather L HL   Lockshin Benjamin N BN   Ahlman Mark A MA   Yao Jianhua J   Playford Martin P MP   Gelfand Joel M JM   Mehta Nehal N NN  

JACC. Cardiovascular imaging 20171018 2 Pt 2


<h4>Objectives</h4>The authors sought to examine the relationship between visceral adipose tissue (VAT) and vascular inflammation (VI) by <sup>18</sup>F-Fluorodeoxyglucose (<sup>18</sup>F-FDG) positron-emission tomography (PET)/computed tomography (CT) in psoriasis (PSO). Furthermore, we evaluated whether treatment of PSO modulated VAT and VI.<h4>Background</h4>PSO, a chronic inflammatory skin disease, is associated with VI by <sup>18</sup>F-FDG PET/CT and increased cardiometabolic risk includin  ...[more]

Similar Datasets

| S-EPMC10582033 | biostudies-literature
| S-EPMC4647251 | biostudies-literature
| S-EPMC8648629 | biostudies-literature
| S-EPMC11309150 | biostudies-literature
| S-EPMC7649810 | biostudies-literature
| S-EPMC7181584 | biostudies-literature
| S-EPMC9834100 | biostudies-literature
| S-EPMC7711422 | biostudies-literature
| S-EPMC4261785 | biostudies-literature